Related Experiment Video

Updated: Jul 7, 2026

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice
06:54

A Modified Inflammatory Pain Model to Study the Analgesic Effect in Mice

Published on: November 15, 2024

COX inhibitors downregulate PDE4D expression in a clinical model of inflammatory pain

X-M Wang1, M Hamza, S M Gordon

  • 1Pain Research Section, National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland, USA.

Clinical Pharmacology and Therapeutics
|February 22, 2008
PubMed

Insights

Ketorolac and rofecoxib did not affect tumor necrosis factor-alpha (TNF-alpha) gene expression. However, these drugs downregulated phosphodiesterase type 4 (PDE4D) expression, suggesting a new mechanism for their pain relief and anti-inflammatory properties.

Area of Science:

  • Pharmacology
  • Inflammation Biology
  • Molecular Biology

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) plays a key role in inflammation.
  • Prostaglandin E(2) (PGE(2)) and cyclic adenosine monophosphate (cAMP) modulate TNF-alpha.
  • Understanding drug mechanisms in inflammation is crucial.

Purpose of the Study:

  • To investigate the effects of ketorolac and rofecoxib on TNF-alpha gene expression.
  • To explore the impact of these drugs on phosphodiesterase type 4 (PDE4D) expression.
  • To identify novel mechanisms underlying the analgesic and anti-inflammatory actions of ketorolac and rofecoxib.

Main Methods:

  • Gene expression analysis using microarray and quantitative real-time polymerase chain reaction (qRT-PCR).
  • Protein expression detection techniques.
  • Analysis of oral mucosal biopsies.

Main Results:

  • Ketorolac and rofecoxib showed no significant effect on TNF-alpha gene expression 3 hours post-surgery.
  • Both ketorolac and rofecoxib significantly downregulated the gene expression of phosphodiesterase type 4 (PDE4D).
  • Downregulation of PDE4D gene and protein expression was observed.

Conclusions:

  • Ketorolac and rofecoxib do not appear to directly inhibit TNF-alpha gene expression in this context.
  • The downregulation of PDE4D by ketorolac and rofecoxib may represent a novel mechanism for their therapeutic effects.
  • Further research into PDE4D inhibition could yield new anti-inflammatory and analgesic strategies.

More Related Videos

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...